Skip to main content

Table 4 Major clinical trials investigating the effect of CLA consumption on immune status; ↑- increased; ↓- decreased; ↔ no change in

From: Pros and cons of CLA consumption: an insight from clinical evidences

Subjects Dose Duration Observation Reference
17 women 3.9 g CLA (Tonalin)/d 93 d ↔ immune status [104]
17 women 3.9 g CLA (Tonalin)/d 93 d ↑ PBMC [105]
↔ circulatory cytokines
71 males 1.7 g 9 & 10-CLA (50:50), Clarinol™/d 12 wk ↑ protective antibodies upon vaccination for hepatitis B [106]
49 healthy men 2.38 g/d 9-CLA or 8 wk ↓ mitogen-induced T-lymphocyte activation [93]
2.52 g/d 10-CLA ↔ circulatory cytokines
55 healthy volunteers 2 g 9 & 10-CLA (50:50)/d or 8 wk ↔ markers of human immune function [107]
1.76 g 9 & 10-CLA (80:20)/d
28 men and women 3 g 9 & 10-CLA (50:50)/d 12 wk ↑ levels of IgA, IgM and IL-10 [108]
↓ TNF-α, IL-1β and delayed type hypersensitivity response
28 mild asthmatic adults 4.5 g CLA/d 12 wk ↑ airway hyperresponsiveness [109]